-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1760 CD79 Expression Is Associated with Cell-of-Origin and Outcome in Diffuse Large B-Cell Lymphoma

Program: Oral and Poster Abstracts
Session: 627. Aggressive Lymphomas: Clinical and Epidemiological: Poster I
Hematology Disease Topics & Pathways:
Research, Lymphomas, non-Hodgkin lymphoma, Translational Research, B Cell lymphoma, Diseases, aggressive lymphoma, Lymphoid Malignancies, Biological Processes, molecular biology, Study Population, Human
Saturday, December 9, 2023, 5:30 PM-7:30 PM

Yusuke Naoi, MD1,2*, Ryota Chijimatsu, PhD2*, Tomohiro Urata, MD3*, Kazutaka Sunami, MD, PhD4, Toshi Imai, MD, PhD5*, Yuichiro Nawa, MD, PhD6*, Yasushi Hiramatsu, MD, PhD7*, Kazuhiko Yamamoto, MD, PhD8*, Soichiro Fujii, MD, PhD9*, Isao Yoshida, MD, PhD10*, Tomofumi Yano, MD, PhD11*, Kazuhiro Ikeuchi, MD3*, Hiroki Kobayashi, MD12*, Katsuma Tani, MD3*, Hiroyuki Murakami, MD3*, Hideki Ujiie13*, Yasuharu Sato, PhD14*, Katsuyoshi Takata, MD, PhD15*, Merrill Boyle, BSc16*, Aixiang Jiang, MS16*, Yoshinobu Maeda, MD, PhD3, David W. Scott, MBChB, PhD17 and Daisuke Ennishi, MD, PhD18

1Department of Hematology, Oncology and Respiratory Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan
2Center of Comprehensive Genomic Medicine, Okayama University Hospital, Okayama, Japan
3Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
4Department of Hematology, National Hospital Organization, Okayama Medical Center, Okayama, Japan
5Hematology and Blood Transfusion, Kochi Health Sciences Center, Kochi, Japan
6Division of Hematology, Ehime Prefectural Central Hospital, Matsuyama, Japan
7Division of Hematology and Oncology, Japanese Red Cross Society Himeji Hospital, Himeji, Japan
8Department of Hematology and Oncology, Okayama City Hospital, Okayama, Japan
9Department of Hematology, Japanese Red Cross Okayama Hospital, Okayama, Japan
10Department of Hematologic Oncology, National Hospital Organization Shikoku Cancer Center, Mastuyama, Japan
11Department of Internal Medicine, Okayama Rosai Hospital, Okayama, Japan
12Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Kamogawa, CHI, Japan
13Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences, Okayama, Japan
14Department of Molecular Hematopathology, Okayama University, Okayama, Japan
15Division of Molecular and Cellular Pathology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
16Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, BC, Canada
17Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada
18Okayama University Hospital, Okayama, Japan

Introduction: CD79B is a target of polatuzumab vedotin, an antibody–drug conjugate, which significantly improved the prognosis of both previously untreated and relapsed/refractory patients with diffuse large B-cell lymphoma (DLBCL). However, the biological and clinical significance of CD79B protein and gene expression have not been fully explored in DLBCL, thus we aimed at examining these relationships.

Methods: We retrospectively analyzed de novo DLBCL patients, who were diagnosed and received rituximab-based immunochemotherapy from 2008 through 2018 in the Okayama Hematology Study Group from Japan. Immunohistochemistry (IHC) staining was performed using a CD79B antibody (AT107-2), and protein expression was assessed based on H-score as described in a previous study (Sehn LH et al. JCO 2020), integrating with publicly available representative bulk RNA sequencing DLBCL datasets (BCC cohort from Ennishi D et al. JCO 2019 and NCI cohort from Schmitz R et al. NEJM 2018). We also performed CD8 and MHC class-I IHC to evaluate the tumor microenvironment. Gene expression profile-based cell-of-origin (COO) classification was performed including double-hit signature (DHITsig), recently renamed the dark zone signature (DZsig), using the NanoString DLBCL90 assay. In addition, simultaneous epitope and transcriptome measurement in single cells from lymphoid tissues was conducted.

Results: CD79B IHC was evaluable in 576 cases. DLBCL90 assay classified the entire cohort into 293 ABC (50.9 %), 189 GCB (32.8 %), 31 DZsig-positive (5.4 %) and 63 unclassified (10.9 %). Furthermore, we dichotomized the cohort into 288 CD79Bhigh cases and 288 CD79Blow cases according to the median CD79B H-score. A dynamic range of CD79B protein expression was observed across COO, where ABC-DLBCL showed the lowest values followed by GCB-DLBCL and DZsig-positive-DLBCL, in ascending order (Kruskal–Wallis test, P < .00001; Figure A). Indeed, CD79Blow cases were significantly enriched in ABC-DLBCL (58 %) compared to GCB-DLBCL (26 %) and DZsig-positive-DLBCL (2 %), respectively (Chi-squared test, P < .001). Consistently, we revealed that CD79B expression was the lowest in ABC-DLBCL compared to GCB-DLBCL and DZsig-positive-DLBCL at the transcriptomic level (Kruskal–Wallis test, P = .011 for BCC cohort and P = .022 for NCI cohort). In addition, we identified different CD79B staining patterns, composed of 433 with cytoplasmic pattern (75 %), 86 with membranous pattern (14.9 %), and 52 cases being IHC negative. These patterns significantly varied across COO (Fisher's exact test, P = .015) and CD79B H-score was the highest in the membranous pattern followed by the cytoplasmic pattern (Kruskal–Wallis test, P < .0001). Of note, the composition of CD8 positive T-cells in CD79Blow tumors was significantly higher than that of CD79Bhigh tumors (Wilcoxon rank sum test, P < .0001). However, MHC class-I expression was decreased in CD79Blow cases compared to CD79Bhigh (Wilcoxon rank sum test, P = .0002), suggesting an immune escape mechanism with downregulation of MHC class-I in the presence of cytotoxic T-cells, which is often seen in solid cancers. Significant association of CD79B expression with COO further prompted us to evaluate CD79B expression in normal germinal center B cells. Notably, the single-cell simultaneous epitope and transcriptome analysis (CITEseq, n = 2) and single-cell RNAseq analysis (n = 6) of reactive lymph nodes revealed that both CD79B gene and protein expression were the lowest in cells exhibiting plasmablastic signatures, followed by light zone and dark zone B cells (Kruskal–Wallis test, P < .0001; Figure B), supporting the relation of CD79B expression to COO subtype in DLBCL. Regarding prognostic impact, CD79Blow group had significantly poorer prognosis in the entire DLBCL cohort (Log-rank test, P = .0005 for overall survival (OS) and P = .008 for progression-free survival (PFS)) and in ABC-DLBCL (Log-rank test, P = .003 for OS and P = .031 for PFS). Moreover, CD79B protein expression was significantly associated with OS after adjusting for International Prognostic Index in the entire DLBCL cohort (Cox regression model; P = .035).

Conclusion: Our study identifies distinct CD79B expression patterns across COO subtypes, with CD79Blow cases enriched in ABC-DLBCL and demonstrating poorer prognosis, suggesting its potential as a prognostic marker and for targeted therapies.

Disclosures: Sunami: Chugai Pharma: Research Funding; Abbvie, Incyte, GlaxoSmithKline, Novartis, Pfizer, BeiGene, Kyowa Kirin, Ono, Otsuka and Chugai: Research Funding; Sanofi, BMS and Janssen: Honoraria, Research Funding. Hiramatsu: AbbVie, Novartis, Kyowa Kirin, Otsuka and Chugai: Honoraria; Sanofi, BMS and Janssen: Honoraria, Research Funding. Yoshida: Janssen, Eisai, Dainipponsumitomo, BMS, MeijiSeika pharma, NipponKayaku and Astrazeneca: Honoraria; Kyowa Kirin, Chugai: Honoraria, Research Funding. Kobayashi: Chugai, Sanofi, Asahi Kasei Pharma, Janssen and Meiji Seika Pharma: Honoraria. Sato: Chugai, Kyowa Kirin and Takeda,: Honoraria; Daiichi Sankyo: Current holder of stock options in a privately-held company, Honoraria. Maeda: Eisai Pharmaceutical Co., Ltd.: Honoraria; Takeda Pharmaceutical Co., Ltd: Honoraria; Kyowa Kirin: Honoraria; AstraZeneca: Research Funding; Chugai Pharmaceutical Co., Ltd.: Honoraria, Research Funding; Astellas: Honoraria, Research Funding; Nippon Shinyaku Pharmaceutical Co., Ltd.: Honoraria, Research Funding; Otsuka Pharmaceutical: Honoraria; Novartis Pharma: Research Funding, Speakers Bureau. Scott: Janssen and Roche: Research Funding; Abbvie, AstraZeneca, Incyte: Consultancy. Ennishi: BMS: Honoraria; Kyowa Hakko Kirin Co., Ltd.: Honoraria; Ono Pharmaceutical: Honoraria; Janssen: Honoraria; Incyte: Honoraria; Eisai: Honoraria, Research Funding; Chugai: Honoraria, Research Funding; Nippon Shinyaku Co.: Honoraria, Research Funding.

*signifies non-member of ASH